In this exploratory phase I trial, a single s.c. dose of CII/calcitriol liposomes was safe, and we observed dose-associated immunomodulatory effects in HLA-DRB1*04:01/01:01+ ACPA+ RA patients on MTX. Here, HLA-DRB1 is linked to rheumatoid arthritis.